Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Zeljko Reiner, Deepak L. Bhatt(Mount Sinai Hospital), Jay M. Edelberg, Patricio López‐Jaramillo(Universidad De Santander), Peter Sinnaeve(Brigham and Women's Hospital), Robert Pordy(Inserm), Shaun G. Goodman(University of Toronto), Andreas M. Zeiher(Goethe University Frankfurt), Nina Gotcheva, Gregory G. Schwartz(University of Colorado Denver), Yong Huo(Sun Yat-sen University), Heinz Drexel(ESCP Business School), Garen Manvelian(Regeneron (United States)), Kenneth W. Mahaffey, Corinne Hanotin(Sanofi (France)), Mirza Dilić(Duke University), Juan-Carlos Prieto(Universidad De Santander), Robert A. Harrington(Cornell University), William J. Sasiela(Inserm), Angèle Moryusef, Harvey D. White(Auckland City Hospital), Jean‐François Tamby(Medical University of South Carolina), Guillaume Lecorps(Inserm), Vera A. Bittner(University of Alabama at Birmingham), Michel Scemama(Sanofi (France)), Philippe Gabríel Steg(Mount Sinai Hospital), Ivan Pećin
Cited by 143
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k